Some brand-name drugmakers are declining to sell their treatments to makers of generic medications, which can block drug analysis needed before low-cost generics enter the market. "We definitely see this as a significant threat to competition," said Markus Meier of the Federal Trade Commission. This practice could restrict access to cheaper medicines that have produced savings of more than a trillion dollars in the past decade, according to generic-drug advocates. Some drugmakers have said they are not required to do business with other makers.

Related Summaries